Xin Lingli, Ye Mei, Gao Yuan, Xiong Qi, Hou Qingxiang
Department of Obstetrics and Gynecology, People's Liberation Army (PLA) Rocket Force Characteristic Medical Center, Beijing, China.
Department of Graduate Administration, General Hospital of Chinese People's Liberation Army (PLA), Beijing, China.
Transl Cancer Res. 2024 Jul 31;13(7):3718-3728. doi: 10.21037/tcr-24-272. Epub 2024 Jun 26.
The prognosis of persistent, recurrent or metastatic cervical and endometrial cancer is poor. Anlotinib is a novel multitarget tyrosine kinase inhibitor (TKI). The efficacy and safety of anlotinib in patients with cervical and endometrial cancer need to be evaluated.
We retrospectively analyzed the efficacy and safety of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancers between March 2020 and June 2023. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were analyzed.
The overall ORR and DCR were 24.14% and 55.17% respectively. The ORR and DCR in patients with cervical cancer were 25.00% and 56.25%; the ORR and DCR in patients with endometrial cancer were 23.08% and 53.85%. The patients received anlotinib plus immunotherapy had significantly higher rate of clinical benefit than those receiving anlotinnb alone (P=0.04). The DCR was significantly higher in patients receiving anlotinib combined with immunotherapy (DCR: 75.00% 30.76%) than those without immunotherapy. The overall median PFS and OS were 12.2 months [95% confidence interval (CI): 6.6-17.8] and 22.3 months (95% CI: 20.9-23.7), respectively. The patients receiving anlotinib plus immunotherapy had significantly longer OS than those without immunotherapy [not reached 12.5 months; hazard ratio (HR): 0.32 (95% CI: 0.1-0.99); P=0.04]. The most common AEs was fatigue (41.4%).
Anlotinib might be a promising agent for persistent, recurrent or metastatic cervical and endometrial cancers with good tolerability. Moreover, anlotinib combined with immunotherapy showed synergistic antitumor effect.
持续性、复发性或转移性宫颈癌和子宫内膜癌的预后较差。安罗替尼是一种新型多靶点酪氨酸激酶抑制剂（TKI）。需要评估安罗替尼在宫颈癌和子宫内膜癌患者中的疗效和安全性。
我们回顾性分析了2020年3月至2023年6月期间安罗替尼在持续性、复发性或转移性宫颈癌和子宫内膜癌患者中的疗效和安全性。分析了客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和不良事件（AE）。
总体ORR和DCR分别为24.14%和55.17%。宫颈癌患者的ORR和DCR分别为25.00%和56.25%；子宫内膜癌患者的ORR和DCR分别为23.08%和53.85%。接受安罗替尼联合免疫治疗的患者临床获益率显著高于单独接受安罗替尼治疗的患者（P=0.04）。接受安罗替尼联合免疫治疗的患者DCR显著高于未接受免疫治疗的患者（DCR：75.00%对30.76%）。总体中位PFS和OS分别为12.2个月[95%置信区间（CI）：-6.6-17.8]和22.3个月（95%CI：20.9-23.7）。接受安罗替尼联合免疫治疗的患者OS显著长于未接受免疫治疗的患者[未达到对12.5个月；风险比（HR）：0.32（95%CI：0.1-0.99）；P=0.04]。最常见的AE是疲劳（41.4%）。
安罗替尼可能是一种有前景的药物，对持续性、复发性或转移性宫颈癌和子宫内膜癌具有良好的耐受性。此外，安罗替尼联合免疫治疗显示出协同抗肿瘤作用。
